{"schema_version":"secwatch.filing_event.v1","accession":"0000898432-22-000500","form_type":"8-K","ticker":"IRMD","cik":"0001325618","company_name":"IRADIMED CORP","filed_at":"2022-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.369926+00:00","generated_at":"2026-06-24T06:51:16.124709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"iRadimed reports record Q2 revenue of $12.7M; GAAP EPS $0.26; full-year guidance raised","bullets":["Q2 revenue $12.7M vs $9.8M YoY (+30%); GAAP diluted EPS $0.26 vs $0.12; non-GAAP EPS $0.26.","Q3 2022 guidance: revenue $13.1-13.3M, GAAP EPS $0.21-0.24, non-GAAP EPS $0.22-0.25.","Full-year 2022 guidance raised: revenue $52.5-53.2M (from $51.4-52.2M), GAAP EPS $0.89-0.95 (from $0.82-0.90), non-GAAP EPS $0.96-1.03.","Gross margin improved to 79.7% from 76.2%; domestic sales 85% of revenue.","Q2 cash from operations $1.6M vs $3.6M YoY; orders exceeded shipments building backlog."],"urls":{"canonical":"https://secwatch.observer/filing/0000898432-22-000500","json":"https://secwatch.observer/filing/0000898432-22-000500.json","markdown":"https://secwatch.observer/filing/0000898432-22-000500.md","text":"https://secwatch.observer/filing/0000898432-22-000500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325618/000089843222000500/0000898432-22-000500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325618/000089843222000500/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:51:16.124709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}